Sphera Funds Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Sphera Funds Management’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-40,000	Closed	-$1.64M	–	159
2017 Q3	$1.64M	Buy	+40,000	New	+$1.26M	0.23%	93
2017 Q2	–	Sell	-40,000	Closed	-$1.45M	–	144
2017 Q1	$1.45M	Hold	40,000	–	–	0.28%	84
2016 Q4	$2M	Sell	40,000 -20,000	-33%	-$1.05M	0.51%	57
2016 Q3	$3.15M	Hold	60,000	–	–	0.51%	49
2016 Q2	$2.48M	Sell	60,000 -20,000	-25%	-$870K	0.64%	49
2016 Q1	$3.25M	Sell	80,000 -65,000	-45%	-$2.23M	0.7%	22
2015 Q4	$6.02M	Sell	145,000 -30,000	-17%	-$1.01M	0.88%	17
2015 Q3	$2.69M	Buy	175,000 +50,000	+40%	+$1.07M	0.34%	72
2015 Q2	$3.1M	Buy	+125,000	New	+$2.78M	0.3%	85
2014 Q2	–	Sell	-90,000	Closed	-$1.77M	–	142
2014 Q1	$1.77M	Buy	+90,000	New	+$1.53M	0.4%	52

Other funds holding FPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Sphera Funds Management's FPRX Position: Q4 2017 in Review

Sphera Funds Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q4 2017, closing a stake of 40,000 shares — an estimated $1.64M sold.

Sphera Funds Management first reported a position in FPRX in Q1 2014 and held it in 10 quarters. The position peaked at $6.02M in Q4 2015. 137 funds tracked by Wall St. Rank hold FPRX as of Q4 2017.

Sphera Funds Management reported no remaining Five Prime Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
Sphera Funds Management sold 40,000 Five Prime Therapeutics, Inc. shares in Q4 2017, an estimated $1.64M.
Sphera Funds Management first reported a position in Five Prime Therapeutics, Inc. in Q1 2014 and held it in 10 quarters.
Sphera Funds Management's Five Prime Therapeutics, Inc. position peaked at $6.02M in Q4 2015.
137 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q4 2017.

Based on Sphera Funds Management's 13F filing for Q4 2017, filed 12 Feb 2018.